Fredun Pharmaceuticals board meeting scheduled for May 25, 2026 to approve Q4 and FY26 audited financial results.
Board to consider recommending final dividend for FY26 and bonus equity shares subject to shareholder approval.
Trading window closure announced until 48 hours after financial results declaration per insider trading regulations.